Abstract
As an important player in stem cells and cancer, CD44 is expressed in multiple isoforms via alternative mRNA splicing. Whether, and if so, how various isoforms play distinct roles in normal stem cells and tumorigenesis remains unclear. In this issue of Oncogene, Zeilstra et al. report studies showing that intestinal stem cells express a specific CD44 variant that promotes intestinal tumorigenesis induced by the activation of Wnt signaling, whereas the more commonly expressed standard CD44 isoform is not expressed by stem cells and does not promote tumor formation. This finding demonstrates an isoform-specific function of CD44 in intestinal stem cells and tumorigenesis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Development of alternative splicing signature in lung squamous cell carcinoma
Medical Oncology Open Access 27 March 2021
-
Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming
Journal of Experimental & Clinical Cancer Research Open Access 19 March 2019
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13–24.
Ponta H, Sherman L, Herrlich PA . CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33–45.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983–3988.
Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104: 10158–10163.
Zoller M . CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254–267.
Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008; 134: 62–73.
Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211–215.
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE . Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006; 12: 1167–1174.
Krause DS, Lazarides K, von Andrian UH, Van Etten RA . Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006; 12: 1175–1180.
Katayama Y, Hidalgo A, Chang J, Peired A, Frenette PS . CD44 is a physiological E-selectin ligand on neutrophils. J Exp Med 2005; 201: 1183–1189.
Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST . Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68: 3655–3661.
Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449: 1003–1007.
Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009; 457: 608–611.
Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064–1074.
Warzecha CC, Carstens RP . Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417–427.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Guo, W., Frenette, P. Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 33, 537–538 (2014). https://doi.org/10.1038/onc.2013.260
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.260
This article is cited by
-
Development of alternative splicing signature in lung squamous cell carcinoma
Medical Oncology (2021)
-
Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming
Journal of Experimental & Clinical Cancer Research (2019)
-
Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas
Oncogene (2019)
-
Generation of CD44 gene-deficient mouse derived induced pluripotent stem cells
In Vitro Cellular & Developmental Biology - Animal (2014)